Abstract
Background: Pancreaticobiliary malignancies respond poorly to conventional chemotherapy, and novel agents are needed. Dolatstatin-10 is a potent antimitotic pentapeptide isolated from the marine mollusk Dolabella auricularia that inhibits microtubule assembly. We conducted 2 parallel phase II trials of dolastatin-10 in patients with advanced hepatobiliary cancers and pancreatic adenocarcinoma. Patients and methods: Eligible patients had histologically-confirmed metastatic pancreatic adenocarcinoma or metastatic, locally advanced or recurrent cancer of the liver, bile duct or gallbladder, and had received no prior chemotherapy for advanced disease. Dolastatin-10 400 μg/m2 was administered intravenously by bolus every 21 days. Restaging CT scans were obtained every 2 cycles. Results: Twenty-eight patients (16 hepatobiliary, including 7 hepatomas, 6 cholangiocarcinomas, 2 gallbladder carcinomas, and 12 pancreatic carcinomas) enrolled; 27 were evaluable for response. There were no objective responses. Grade 3/4 neutropenia occurred in 59% of patients and neutropenic fever in 18%. Median and 1-year survival were 5.0 months and 17% for the pancreatic cancer patients, and 3.0 months and 29% for the hepatobiliary patients. Median time to progression was 1.3 months for the pancreatic cancer patients and 1.6 months for the hepatobiliary patients. Conclusions: Dolastatin-10 is inactive against hepatobiliary and pancreatic carcinomas.
Similar content being viewed by others
References
Burris HA 3rd, Moore MJ, Andersen J, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15: 2403–2413, 1997
Scheithauer W: Review of gemcitabine in biliary tract carcinoma. Semin Oncol 29(6 Suppl 20): 40–45, 2002
Misra S, Chaturvedi A, Misra NC, Sharma ID: Carcinoma of the gallbladder. Lancet Oncology 4: 167–176, 2004
Nowak AK, Chow PKH, Finlay M: Systemic therapy for advanced hepatocellular carcinoma: A review. Eur J Ca 40: 1474–1484, 2004
Pettit GR, Kamano Y, Herald CT, Tuinman AA, Boettner FE, Kizu H, Schmidt JM, Baczynskyj L, Tomer KB, Bontems RJ: The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin-10. J Am Chem Soc 109: 6883–6885, 1987
Bai R, Pettit GR, Hamel E: Dolastatin-10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 39: 1941–1949, 1990
Aherne GW, Hardcastle A, Valenti M, Bryant A, Rogers P, Pettit GR, Srirangam JK, Kelland: Antitumor evaluation of dolostatins 10 and 15 and their measurement in plasma by radioimmunoassay. Cancer Chemother Pharmacol 38: 225–232, 1996
Kalemkerian GP, OU X, Adil MR, Rosati R, Khoulani MM, Madan SK, Pettit GR: Activity of Dolastatin-10 against small cell lung cancer in vitro and in vivo: Induction of apoptosis and bcl-2 modification. Cancer Chemother Pharmacol 43: 507–515, 1999
Turner T, Jackson WH, Pettit GR, Wells A, Kraft AS: Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusk. Prostate 34: 175–81, 1998
Pitot HC, McElroy EA, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM: Phase I trial of Dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 5: 525–531, 1999
Garteiz DA, Madden T, Beck DE, Huie WR, McManus KT, Abbruzzese JL, Chen W, Newman RA: Quantitation of Dolastatin-10 using HPLC/electrospray ionization mass spectrometry: Application in a phase I clinical trial. Cancer Chemother Pharmacol 41: 299–306, 1998
Madden T, Tran HT, Beck D, Huie R, Newman RA, Pusztai L, Wright JJ, Abbruzzese JL: Novel marine-derived anticancer agents: A phase I clinical, pharmacological, and pharmacodynamic study of dolostatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 6: 1293–1301, 2000
Simon, R: Optimal Two-Stage Designs for Phase II Clinical Trials. Controlled Clin. Trial. 10: 1–10. 1989
Krug LM, Miller VA, Kalemkerian GP, Kraut MJ, Ng KK, Heelan RT, Pizzo BA, Perez W, McClean N, Kris MG: Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Ann Oncol 11: 227–228, 2000
Margolin K, Longmate J, Synold TW, Gandara DR, Weber J, Gonzalez R, Johansen MJ, Newman R, Baratta T, Doroshow JH: Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the California Cancer Consortium. Invest New Drugs 19: 335–340, 2001
Saad ED, Kraut EH, Hoff PM, Moore DF, Jones D, Pazdur R, Abbruzzese JL: Phase II study of dolastatin-10 as first-line treatment of advanced colorectal cancer. Am J Clin Oncol 25(5): 451–453, 2002
Hoffman MA, Blessing JA, Lentz SS: A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 1: 95–8, 2003
Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, Hussain M: Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Research 6: 4205–4208, 2000
Verdier-Pinard P, Kepler JA, Pettit GR, Hamel E: Sustained intracellular retention of dolastatin 10 causes potent antimitotic activity. Mol Pharmacol 57: 180–187, 2000
Singh DA, Kindler HL, Eng C, Skoog L, Lenz H-J, Taber D, Vokes EE: Phase II trial of the epothilone B analog BMS-247550 in patients with hepatobiliary cancer. Proc Am Soc Clin Oncol 22: 281, 2003
Whitehead RP, McCoy SA, Rivkin SE, Gross HM, Conrad ME, Abbruzzese JL: A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: A Southwest Oncology Group Study. Proc Am Soc Clin Oncol 23: 315, 2004
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported in part by National Cancer Institute Grant No. UO1CA63187 -04.
Rights and permissions
About this article
Cite this article
Kindler, H.L., Tothy, P.K., Wolff, R. et al. Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs 23, 489–493 (2005). https://doi.org/10.1007/s10637-005-2909-x
Issue Date:
DOI: https://doi.org/10.1007/s10637-005-2909-x